Subacute cutaneous lupus erythematosus associated with tamoxifen therapy: Two cases [8]

Dermatology

Volumn 210, Issue 3, 2005, Pages 251-252

  Fumal, I ^a   Danchin, A ^a   Cosserat, F ^b   Barbaud, A ^a   Schmutz, J L ^a,c  

^a Service de Dermatologie   (France)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

^c SERVICE DE DERMATOLOGIE   (France)

Author keywords

Breast cancer; Lupus erythematosus; Oestrogen antagonist; Subacute cutaneous lupus erythematosus; Tamoxifen

Indexed keywords

AMIODARONE; AROMATASE INHIBITOR; FUROSEMIDE; HYDROXYCHLOROQUINE; LYSINE ACETYLSALICYLATE; NIFEDIPINE; STEROID; TAMOXIFEN;

AGED; ANAMNESIS; BREAST ADENOCARCINOMA; BREAST CANCER; CASE REPORT; DERMIS; DISEASE ASSOCIATION; DRUG ERUPTION; EPIDERMIS; ERYTHEMA; FEMALE; HEART DISEASE; HISTOPATHOLOGY; HUMAN; IMMUNOFLUORESCENCE; LABORATORY TEST; LETTER; LIVER CELL CARCINOMA; LYMPHOCYTIC INFILTRATION; PRIORITY JOURNAL; PRURITUS; SEROLOGY; SKIN BIOPSY; SKIN DISEASE; SKIN LUPUS ERYTHEMATOSUS; TREATMENT WITHDRAWAL;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, HEPATOCELLULAR; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; LIVER NEOPLASMS; LUPUS ERYTHEMATOSUS, CUTANEOUS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 17244363075     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000083798     Document Type: Letter

References (10)

1. Sontheimer RD, Gillian IJR: Subacute cutaneous lupus erythematosus: A cutaneous marker for a distinct lupus erythematosus subset. Arch Dermatol 1979;115:1409-1415.
2. Ho C, Shumack S, Morris D: Subacute cutaneous lupus erythematosus associated with hepatocellular carcinoma. Austral J Dermatol 2001;42: 110-113.
3. Schewach-Millet M, Shipro D, Ziv R, Trav H: Subacute cutaneous lupus erythematosus associated with breast carcinoma. J Am Acad Dermatol 1988;19:406-408.
4. Noël B, Panizzon R: Lupus-like syndrome associated with statin therapy. Dermatology 2004;208:276-277.
5. Callen JP: Drug-induced cutaneous lupus erythematosus, a distinct syndrome that is frequently unrecognized. J Am Acad Dermatol 2001;45:315-316.
6. Crowson AN, Magro CM: Subacute cutaneous lupus erythematosus arising in the setting of calcium channel blocker therapy. Hum Pathol 1997;28: 67-73.
7. Thylan S: The beneficial effect of the estrogen antagonist tamoxifen on experimental systemic lupus erythematosus. J Rheumatol 1995;22:1606-1607.
8. Wu WM, Suen JL, Lin BF, Chiang BL: Tamoxifen alleviates disease severity and decreases double negative T cells in autoimmune MRL-1pr/1pr mice. Immunology 2000;100:110-118.
9. 1 female mice are associated with specific reduction of IgG3 autoantibodies. Ann Rheum Dis 2003;62:341-346.
10. Dayan M, Zinger H, Kalush F, et al: The beneficial effects of treatment with tamoxifen and anti-oestradiol antibody on experimental systemic lupus erythematosus are associated with cytokine modulations. Immunology 1997;90:101-108.